Kris MG - Search Results

1

Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.

Girard N, Shen R, Guo T, Zakowski MF, Heguy A, Riely GJ, Huang J, Lau C, Lash AE, Ladanyi M, Viale A, Antonescu CR, Travis WD, Rusch VW, Kris MG, Pao W. Girard N, et al. Among authors: kris mg. Clin Cancer Res. 2009 Nov 15;15(22):6790-9. doi: 10.1158/1078-0432.CCR-09-0644. Epub 2009 Oct 27. Clin Cancer Res. 2009. PMID: 19861435 Free PMC article.

2

Ras oncogene point mutation: an infrequent event in bronchioloalveolar cancer.

Rusch VW, Reuter VE, Kris MG, Kurie J, Miller WH Jr, Nanus DM, Albino AP, Dmitrovsky E. Rusch VW, et al. Among authors: kris mg. J Thorac Cardiovasc Surg. 1992 Nov;104(5):1465-9. J Thorac Cardiovasc Surg. 1992. PMID: 1331621

3

Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer.

Rusch V, Klimstra D, Venkatraman E, Oliver J, Martini N, Gralla R, Kris M, Dmitrovsky E. Rusch V, et al. Cancer Res. 1995 Nov 1;55(21):5038-42. Cancer Res. 1995. PMID: 7585548

4

Factors influencing ten-year survival in resected stages I to IIIa non-small cell lung cancer.

Martini N, Rusch VW, Bains MS, Kris MG, Downey RJ, Flehinger BJ, Ginsberg RJ. Martini N, et al. Among authors: kris mg. J Thorac Cardiovasc Surg. 1999 Jan;117(1):32-6; discussion 37-8. doi: 10.1016/s0022-5223(99)70467-8. J Thorac Cardiovasc Surg. 1999. PMID: 9869756 Free article.

5

Induction chemotherapy employing dose-intense cisplatin with mitomycin and vinblastine (MVP400), followed by thoracic surgery or irradiation, for patients with stage III nonsmall cell lung carcinoma.

Ng KK, Kris MG, Ginsberg RJ, Heelan RT, Pisters KM, Miller VA, Grant SC, Bains M, Rusch V, Rosenzweig KE, Martini N. Ng KK, et al. Among authors: kris mg. Cancer. 1999 Oct 1;86(7):1189-97. doi: 10.1002/(sici)1097-0142(19991001)86:7<1189::aid-cncr13>3.0.co;2-n. Cancer. 1999. PMID: 10506703 Clinical Trial.

6

The clinical course of lung carcinoma in patients with chronic lymphocytic leukemia.

Parekh K, Rusch V, Kris M. Parekh K, et al. Cancer. 1999 Nov 1;86(9):1720-3. Cancer. 1999. PMID: 10547544

7

Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.

Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Sirotnak FM, et al. Among authors: kris mg. Clin Cancer Res. 2000 Dec;6(12):4885-92. Clin Cancer Res. 2000. PMID: 11156248

8

Long-term results of combined-modality therapy in resectable non-small-cell lung cancer.

Martin J, Ginsberg RJ, Venkatraman ES, Bains MS, Downey RJ, Korst RJ, Kris MG, Rusch VW. Martin J, et al. Among authors: kris mg. J Clin Oncol. 2002 Apr 15;20(8):1989-95. doi: 10.1200/JCO.2002.08.092. J Clin Oncol. 2002. PMID: 11956257

9

The clinical course of nonsmall cell lung carcinoma in survivors of Hodgkin disease.

Laurie SA, Kris MG, Portlock CS, Rosenzweig KE, Miller VA, Krug LM, Rusch VW. Laurie SA, et al. Among authors: kris mg. Cancer. 2002 Jul 1;95(1):119-26. doi: 10.1002/cncr.10628. Cancer. 2002. PMID: 12115325 Free article.

10

A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis.

Downey RJ, Ng KK, Kris MG, Bains MS, Miller VA, Heelan R, Bilsky M, Ginsberg R, Rusch VW. Downey RJ, et al. Among authors: kris mg. Lung Cancer. 2002 Nov;38(2):193-7. doi: 10.1016/s0169-5002(02)00183-6. Lung Cancer. 2002. PMID: 12399132 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

525 results

Search Page

Filters